Bank of New York Mellon’s TriSalus Life Sciences TLSI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$507K Buy
111,534
+45,730
+69% +$182K ﹤0.01% 3749
2026
Q1
$263K Buy
65,804
+1,200
+2% +$5.88K ﹤0.01% 3907
2025
Q4
$451K Buy
64,604
+17,900
+38% +$100K ﹤0.01% 3669
2025
Q3
$217K Buy
46,704
+4,903
+12% +$23K ﹤0.01% 3978
2025
Q2
$228K Buy
+41,801
New +$224K ﹤0.01% 3932

Other funds holding TLSI

Bank of New York Mellon's TLSI Position: Q2 2026 in Review

Bank of New York Mellon increased its TriSalus Life Sciences (TLSI) stake by 69% in Q2 2026, buying an estimated $182K and bringing the position to 111,534 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #3749.

Bank of New York Mellon first reported a position in TLSI in Q2 2025 and has held it in 5 quarters since. 33 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

  • Bank of New York Mellon held 111,534 shares of TriSalus Life Sciences worth $507K as of Q2 2026.
  • Bank of New York Mellon bought 45,730 TriSalus Life Sciences shares in Q2 2026, an estimated $182K.
  • TriSalus Life Sciences made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3749 holding.
  • Bank of New York Mellon first reported a position in TriSalus Life Sciences in Q2 2025 and has held it in 5 quarters since.
  • 33 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.